Edgewise Therapeutics Stock Investor Sentiment

EWTX Stock  USD 31.98  0.22  0.68%   
Slightly above 59% of Edgewise Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Edgewise Therapeutics suggests that many traders are alarmed. Edgewise Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Edgewise Therapeutics' earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

41

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Edgewise Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Edgewise Therapeutics.

Edgewise Historical Sentiment

Although Edgewise Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Edgewise, such as negative comments on social media and news outlets, may cause fear in the market and push Edgewise Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Edgewise.
  

Edgewise Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Edgewise Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at news.google.com         
Edgewise Therapeutics Trading 6.9 percent Higher - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 5208 shares by Carruthers R Michael of Edgewise Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Price T Rowe Associates Inc. MD Sells 109,647 Shares of Edgewise Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Piper Sandler maintains target on Edgewise Therapeutics stock - Investing.com
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Carruthers R Michael of 23125 shares of Edgewise Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at simplywall.st         
We Think Edgewise Therapeutics Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over three months ago at finance.yahoo.com         
Heres Why Were Not Too Worried About Edgewise Therapeutics Cash Burn Situation
Yahoo News
over three months ago at businesswire.com         
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
businesswire News
over three months ago at investorplace.com         
EWTX Stock Earnings Edgewise Therapeutics Beats EPS for Q2 2024
sbwire news
over three months ago at news.google.com         
Edgewise Therapeutics Strong Open Label Data Makes For A Bullish Signal - Seeking Alpha
Google News at Macroaxis
over three months ago at investorplace.com         
Disposition of 3813 shares by John Moore of Edgewise Therapeutics at 20.0065 subject to Rule 16b-3
sbwire news
over three months ago at news.google.com         
ProShare Advisors LLC Increases Position in Edgewise Therapeutics, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Edgewise Therapeutics, Inc. Shares Bought by Ameritas Investment Partners Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Edgewise Therapeutics Outperform Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Dont Be Scared of Heights J.P. Morgan Suggests 2 Stocks to Buy - Markets Insider
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Edgewise Therapeutics that are available to investors today. That information is available publicly through Edgewise media outlets and privately through word of mouth or via Edgewise internal channels. However, regardless of the origin, that massive amount of Edgewise data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Edgewise Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Edgewise Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Edgewise Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Edgewise Therapeutics alpha.

Edgewise Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by John Moore of 23125 shares of Edgewise Therapeutics subject to Rule 16b-3
08/30/2024
2
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstru...
09/17/2024
3
Disposition of 20922 shares by John Moore of Edgewise Therapeutics at 27.6295 subject to Rule 16b-3
09/23/2024
4
Edgewise Therapeutics CMO sells 202k in company stock
09/25/2024
5
Analysts Think Theres Still Time To Get In On Edgewise
09/30/2024
6
Edgewise Therapeutics to Present on Sevasemten for Becker Muscular Dystrophy at the 29th International Annual Congress of the World Muscle Society
10/01/2024
7
Edgewise Therapeutics Insiders Sold US2.6m Of Shares Suggesting Hesitancy
10/04/2024
8
Acquisition by Carruthers R Michael of 70000 shares of Edgewise Therapeutics at 0.71 subject to Rule 16b-3
10/11/2024
9
Acquisition by Behrad Derakhshan of 4800 shares of Edgewise Therapeutics at 1.93 subject to Rule 16b-3
10/25/2024
10
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - StockTitan
11/07/2024
11
Orbimed Advisors LLC Adjusts Stake in Edgewise Therapeutics Inc
11/13/2024
12
Edgewise Therapeutics shares get Outperform rating from Evercore ISI on potential
11/22/2024

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.